Evidence map›Paper›PMID 25713721›Full record

ArticleClinical kidney journal2015

A novel LMX1B mutation in a family with end-stage renal disease of 'unknown cause'.

Noel Edwards, Sarah J Rice, Shreya Raman, Ann Marie Hynes, Shalabh Srivastava, Iain Moore, Mohamed Al-Hamed, Yaobo Xu, Mauro Santibanez-Koref, David T Thwaites and 2 more

Open access · hybridAbstract read
In one paragraph

Article in Clinical kidney journal, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Look Alike, Sound Alike: Phenocopies in Steroid-Resistant Nephrotic Syndrome.International journal of environmental research and public health · 2020
    Review
  8. Article
  9. Article
  10. Modeling congenital kidney diseases inDisease models & mechanisms · 2019
    Review
  11. Article
  12. Article
  13. Genomic medicine for kidney disease.Nature reviews. Nephrology · 2018
    Review
  14. Review
  15. Hereditary Podocytopathies in Adults: The Next Generation.Kidney diseases (Basel, Switzerland) · 2017
    Review
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 1 country.

Noel EdwardsInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK ; Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Framlington Place , Newcastle University , Newcastle upon Tyne , UK.
Sarah J RiceInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK ; Institute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Framlington Place , Newcastle University , Newcastle upon Tyne , UK.
Shreya RamanRoyal Victoria Infirmary , Newcastle upon Tyne NHS Hospitals Foundation Trust , Newcastle upon Tyne , UK.
Ann Marie HynesInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
Shalabh SrivastavaInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
Iain MooreRenal Unit , Sunderland Royal Infirmary , Sunderland , UK.
Mohamed Al-HamedInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
Yaobo XuInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
Mauro Santibanez-KorefInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
David T ThwaitesInstitute for Cell and Molecular Biosciences, Faculty of Medical Sciences, Framlington Place , Newcastle University , Newcastle upon Tyne , UK.
Daniel P GaleUCL Centre for Nephrology , Royal Free Hospital , London , UK.
John A SayerInstitute of Genetic Medicine , International Centre for Life, Newcastle University , Newcastle upon Tyne , UK.
Centre for Life · GBNewcastle University · GBRoyal Victoria Infirmary · GBSunderland Eye Infirmary · GBThe Royal Free Hospital · GB

Funding

Medical Research Council G1002528
6 · The paper itself

Abstract

End-stage renal disease (ESRD) presenting in a familial autosomal dominant pattern points to an underlying monogenic cause. Nail-patella syndrome (NPS) is an autosomal dominant disorder that may lead to ESRD caused by mutations in the transcription factor LMX1B. Renal-limited forms of this disease, termed nail-patella-like renal disease (NPLRD), and LMX1B nephropathy have recently been described. We report a large family, from the North East of England, with seven affected members with varying phenotypes of renal disease, ranging from ESRD at 28 years of age to microscopic haematuria and proteinuria and relatively preserved renal function. In this family, there were no extra-renal manifestations to suggest NPS. Genome-wide linkage studies and inheritance by descent (IBD) suggested disease loci on Chromosome 1 and 9. Whole exome sequencing (WES) analysis identified a novel sequence variant (p.R249Q) in the LMX1B gene in each of the three samples submitted, which was confirmed using Sanger sequencing. The variant segregated with the disease in all affected individuals. In silico modelling revealed that R249 is putatively located in close proximity to the DNA phosphoskeleton, supporting a role for this residue in the interaction between the LMX1B homeodomain and its target DNA. WES and analysis of potential target genes, including CD2AP, NPHS2, COL4A3, COL4A4 and COL4A5, did not reveal any co-inherited pathogenic variants. In conclusion, we confirm a novel LMX1B mutation in a large family with an autosomal dominant pattern of nephropathy. This report confirms that LMX1B mutations may cause a glomerulopathy without extra-renal manifestations. A molecular genetic diagnosis of LMX1B nephropathy thus provides a definitive diagnosis, prevents the need for renal biopsies and allows at risk family members to be screened.

Indexed as

end-stage renal diseaseLMX1Bpodocytopathyproteinuriatranscription factor

Identifiers

PMID25713721
PMCPMC4310431
OpenAlexW2166808951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.